| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Guo Renfeng | Chief Scientific Officer, Director | C/O INFLARX N.V., WINZERLAER STREET 2, JENA, GERMANY | /s/ Christian Schmid, Attorney-in-Fact | 18 Mar 2026 | 0001730244 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| holding | IFRX | Ordinary Shares | 1,762,144 | 18 Mar 2026 | Direct |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| holding | IFRX | Stock Option (Right to Buy) | 18 Mar 2026 | Ordinary Shares | 336,672 | $1.86 | Direct | F1 | ||||||
| holding | IFRX | Stock Option (Right to Buy) | 18 Mar 2026 | Ordinary Shares | 623,610 | $1.86 | Direct | F2 | ||||||
| holding | IFRX | Stock Option (Right to Buy) | 18 Mar 2026 | Ordinary Shares | 5,409 | $1.86 | Direct | F3 | ||||||
| holding | IFRX | Stock Option (Right to Buy) | 18 Mar 2026 | Ordinary Shares | 275,000 | $1.86 | Direct | F4 | ||||||
| holding | IFRX | Stock Option (Right to Buy) | 18 Mar 2026 | Ordinary Shares | 88,006 | $1.86 | Direct | F5 | ||||||
| holding | IFRX | Stock Option (Right to Buy) | 18 Mar 2026 | Ordinary Shares | 430,500 | $1.86 | Direct | F6 | ||||||
| holding | IFRX | Stock Option (Right to Buy) | 18 Mar 2026 | Ordinary Shares | 55,000 | $2.44 | Direct | F7 | ||||||
| holding | IFRX | Stock Option (Right to Buy) | 18 Mar 2026 | Ordinary Shares | 430,500 | $2.37 | Direct | F8 | ||||||
| holding | IFRX | Stock Option (Right to Buy) | 18 Mar 2026 | Ordinary Shares | 500,000 | $1.79 | Direct | F9 | ||||||
| holding | IFRX | Stock Option (Right to Buy) | 18 Mar 2026 | Ordinary Shares | 500,000 | $2.41 | Direct | F10 | ||||||
| holding | IFRX | Stock Option (Right to Buy) | 18 Mar 2026 | Ordinary Shares | 571,500 | $1.17 | Direct | F11 | ||||||
| holding | IFRX | Performance Stock Option (Right to Buy) | 18 Mar 2026 | Ordinary Shares | 171,450 | $1.17 | Direct | F12 |
| Id | Content |
|---|---|
| F1 | This option was granted on November 18, 2016 and is fully vested and exercisable as of the date hereof. |
| F2 | This option was granted on December 13, 2017 and is fully vested and exercisable as of the date hereof. |
| F3 | This option was granted on November 20, 2018 and is fully vested and exercisable as of the date hereof. |
| F4 | This option was granted on January 4, 2021 and is fully vested and exercisable as of the date hereof. |
| F5 | This option was granted on July 2, 2021 and is fully vested and exercisable as of the date hereof. |
| F6 | This option was granted on January 12, 2022 and is fully vested and exercisable as of the date hereof. |
| F7 | This option was granted on November 21, 2022 and is fully vested and exercisable as of the date hereof. |
| F8 | This option was granted on January 24, 2023 and is fully vested and exercisable as of the date hereof. |
| F9 | This option was granted on January 5, 2024 and is fully vested and exercisable as of the date hereof. |
| F10 | This option was granted on January 3, 2025 and is fully vested and exercisable as of the date hereof. |
| F11 | This option was granted on January 6, 2026 and will vest and become exercisable in four equal installments of 142,875 shares on each quarterly anniversary of such grant date, subject to continued service through such dates. |
| F12 | This option shall vest depending upon achievement of the following performance criteria: (i) 50% shall vest if a certain financing event takes place before the fourth quarter of 2026 and (ii) 50% shall vest if the average Ordinary Share price for quarter four of 2026 exceeds $1.50. |
Exhibit List - Exhibit 24.1 Power of Attorney